Chapter 65 Antimicrobial Therapy

  1. Smith MA, Ross MW: Postoperative infection with Actinobacillus spp in horses: 10 cases (1995-2000). J Am Vet Med Assoc 221(9):1306–1310, 2002. PUBMED Abstract
  2. Sternberg S, Greko C, Olsson-Liljequist B: Antimicrobial susceptibility of equine isolates of Actinobacillus spp. and identification of beta-lactamases in some strains. Microb Drug Resist 5(4):289–293, 1999. PUBMED Abstract
  3. Sequin JC, Walker RD, Caron JP, et al: Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: potential human-to-animal transmission. J Clin Microbiol 37:1459–1463, 1999. PUBMED Abstract
  4. Methicillin-resistant Staphylococcus aureus: an emerging problem in horses? J Am Vet Med Assoc 223(10): 1399–1400, 2003.
  5. Weese JS, Rousseau J, Traub-Dargatz, et al: Community-associated methicillin-resistant Staphylococcus aureus in horses and humans who work with horses. J Am Vet Med Assoc 226:580–583, 2005. PUBMED Abstract
  6. Trostle SS, Peavey CL, King DS, et al: Treatment of methicillin-resistant Staphylococcus epidermidis infection following repair of an ulnar fracture and humeroradial joint luxation in a horse. J Am Vet Med Assoc 218(4):554–559, 2001. PUBMED Abstract
  7. Orsini JA, Ramberg CF Jr, Benson CE, et al: Vancomycin kinetics in plasma and synovial fluid following intravenous administration in horses. J Vet Pharmacol Ther 15(4):351–363, 1992. PUBMED Abstract
  8. Sieber S, Gerber V, Jandova V, et al: Evolution of multidrug-resistant Staphylococcus aureus infections in horses and colonized personnel in an equine clinic between 2005 and 2010. Microb Drug Resist 17(3):465–468, 2011. PUBMED Abstract
  9. Sweeney CR, Holcombe SJ, Barningham SC, et al: Aerobic and anaerobic bacterial isolates from horses with pneumonia or pleuropneumonia and antimicrobial susceptibility patterns of the aerobes. J Am Vet Med Assoc 198:839–842, 1991. PUBMED Abstract
  10. Jang SS, Breher JE, Dabaco LA, et al: Organisms isolated from dogs and cats with anaerobic infections and susceptibility to selected antimicrobial agents. J Am Vet Med Assoc 210:1610–1614, 1997. PUBMED Abstract
  11. Hirsh DC, Indiveri MC, Jang SS, et al: Changes in prevalence and susceptibility of obligate anaerobes in clinical veterinary practice. J Am Vet Med Assoc 186:1086–1089, 1985. PUBMED Abstract
  12. Oluoch AO, Kim CH, Weisiger RM, et al: Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998). J Am Vet Med Assoc 218:381–384, 2001. PUBMED Abstract
  13. Walker AL, Jang SS, Hirsh DC: Bacteria associated with pyothorax of dogs and cats: 98 cases (1989-1998). J Am Vet Med Assoc 216: 359–363, 2000. PUBMED Abstract
  14. Sanchez LC, Giguère S, Lester GD: Factors associated with survival of neonatal foals with bacteremia and racing performance of surviving Thoroughbreds: 423 cases (1982-2007). J Am Vet Med Assoc 233(9):1446–1452, 2008. PUBMED Abstract
  15. Orsini JA, Benson CE, Spencer PA, et al: Resistance to gentamicin and amikacin of gram-negative organisms isolated from horses. Am J Vet Res 50:923–925, 1989. PUBMED Abstract
  16. Dowling PM, Wilson RC, Tyler JW, et al: Pharmacokinetics of ciprofloxacin in ponies. J Vet Pharmacol Ther 18:7–12, 1995. PUBMED Abstract
  17. Yamarik TA, Wilson WD, Wiebe VJ, et al: Pharmacokinetics and toxicity of ciprofloxacin in adult horses. J Vet Pharmacol Ther 33(6):587–594, 2010. PUBMED Abstract
  18. Latimer FG, Colitz CM, Campbell NB, et al: Pharmacokinetics of fluconazole following intravenous and oral administration and body fluid concentrations of fluconazole following repeated oral dosing in horses. Am J Vet Res 62(10):1606–1611, 2001. PUBMED Abstract
  19. Clinical and Laboratory Standards Institute (CLSI): Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline M23-MA2, ed 2, Wayne, PA, 2001, The Institute.
  20. Clinical and Laboratory Standards Institute (CLSI): Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobial agents; approved guideline M37-MA2, ed 2, Wayne, PA, 2002, The Institute.
  21. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial disk and dilution susceptibility tests for bacterial isolated from animal; approved standard M31-MA2, ed 2, Wayne, PA, 2002, The Institute.
  22. Hyatt JM, McKinnon PS, Zimmer GS, et al: The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 28:143–160, 1995. PUBMED Abstract
  23. Nicolau DP, Quintiliani R, Nightingale CH: Antibiotic kinetics and dynamics for the clinician. Med Clin North Am 79:477–495, 1995. PUBMED Abstract
  24. Turnidge JD: The pharmacodynamics of β-lactams. Clin Infect Dis 27:10–22, 1998. PUBMED Abstract
  25. Freeman CD, Nicolau DP, Belliveau PP, et al: Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 39:677, 1997. PUBMED Abstract
  26. Maglio D, Nightingale CH, Nicolau DP: Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents 19:341–348, 2002. PUBMED Abstract
  27. Tudor RA, Papich MG, Redding WR: Gentamicin disposition and dosage determination of once daily administration of gentamicin sulfate in horses after abdominal surgery. J Am Vet Med Assoc 215(4):503–506, 1999.
  28. Dudley MN: Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 91(suppl 6A):45–50, 1991. PUBMED Abstract
  29. Wright DH, Brown GH, Peterson ML, et al: Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46:669–683, 2000. PUBMED Abstract
  30. Papich MG, Riviere JE: Fluoroquinolones. In Adams HR, editor: Veterinary pharmacology and therapeutics, ed 8, Ames, 2001, Iowa State University Press.
  31. Lode H, Borner K, Koeppe P: Pharmacodynamics of fluoroquinolones. Clin Infect Dis 27: 33–39, 1998. PUBMED Abstract
  32. Walker RD: Fluoroquinolones. In Prescott JF, Baggot JD, Walker RD, editors: Antimicrobial therapy in veterinary medicine, ed 3, Ames, IA, 2000, Iowa State University Press.
  33. Papich MG, Van Camp SD, Cole J, et al: Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after IV administration of enrofloxacin to mares. J Vet Pharmacol Ther 25:343–350, 2002. PUBMED Abstract
  34. Giguère S, Sweeney RW, Bélanger M: Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses. Am J Vet Res 57:1025–1030, 1996. PUBMED Abstract
  35. Langston VC, Sedrish S, Boothe DM: Disposition of single-dose oral enrofloxacin in the horse. J Vet Pharmacol Ther 19:316–319, 1996. PUBMED Abstract
  36. Pyörälä S, Panu S, Kaartinen L: Single dose pharmacokinetics of ciprofloxacin in horses. Proc EAVPT 45–46, 1994.
  37. Davis JL, MK Sheats, MG Papich: Pharmacokinetics of intravenous enrofloxacin and its active metabolite ciprofloxacin in hospitalized horses. J Vet Int Med 23(3):726, 2009.
  38. Craig WA: Pharmacodynamics of antimicrobials: general concepts and applications. In Nightingale CH, Murakawa T, Ambrose PG, editors: Pharmacodynamics of antimicrobials: general concepts and applications, New York, 2002, Marcel Dekker, pp 1–22.
  39. Davis JL, Gardner SY, Jones SL, et al: Pharmacokinetics of azithromycin in foals after IV and oral dose and disposition into phagocytes. J Vet Pharmacol Ther 25:99–104, 2002. PUBMED Abstract
  40. Jacks S, Giguère S, Gronwall RR, et al: Disposition of oral clarithromycin in foals. J Vet Pharmacol Ther 25(5):359–362, 2002. PUBMED Abstract
  41. Bertone AL, McIlwraith CW, Jones RL, et al: Comparison of various treatments for experimentally induced equine infectious arthritis. Am J Vet Res 48:519–529, 1987. PUBMED Abstract
  42. Nix DE, Goodwin SD, Peloquin CA, et al: Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 35:1953–1959, 1991. PUBMED Abstract
  43. Ryan DM: Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 31(suppl D):1–16, 1993. PUBMED Abstract
  44. Anderson BH, Firth EC, Whittem T: The disposition of gentamicin in equine plasma, synovial fluid and lymph. J Vet Pharmacol Ther 18:124–131, 1995. PUBMED Abstract
  45. Bowman KF, Dix LP, Riond JL, et al: Prediction of pharmacokinetic profiles of ampicillin sodium, gentamicin sulfate, and combination ampicillin sodium–gentamicin sulfate in serum and synovia of healthy horses. Am J Vet Res 47:1590–1595, 1986. PUBMED Abstract
  46. Firth EC, Klein WR, Nouws JFM, et al: Effect of induced synovial inflammation on pharmacokinetics and synovial concentrations of sodium ampicillin and kanamycin sulfate after systemic administration in ponies. J Vet Pharmacol Ther 11:56–62, 1988. PUBMED Abstract
  47. Brown MP, Embertson RM, Gronwall RR, et al: Amikacin sulfate in mares: pharmacokinetics and body fluid and endometrial concentrations after repeated intramuscular administration. Am J Vet Res 45(8):1610–1613, 1984. PUBMED Abstract
  48. Baldwin DR, Honeybourne D, Wise R: Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 36:1165–1175, 1992. PUBMED Abstract
  49. Zertuche JML, Hillidge CJ: Therapeutic considerations for Rhodococcus equi pneumonia in foals. Compend Contin Educ Pract Vet 9:965–971, 1987.
  50. Pascual A: Uptake and intracellular activity of antimicrobial agents in phagocytic cells. Rev Med Microbiol 6:228–235, 1995.
  51. Davis JL, Salmon JH, Papich MG: Pharmacokinetics and tissue distribution of doxycycline in the horse following administration of single and multiple oral doses. Am J Vet Res 67(2):310–316, 2006. PUBMED Abstract
  52. Habash M, Reid G: Microbial biofilms: their development and significance for medical device-related infections. J Clin Pharmacol 39:887–898, 1999. PUBMED Abstract
  53. Smith AW: Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv Drug Deliv Rev 57:1539–1550, 2005. PUBMED Abstract
  54. Van Duijkeren E, Vulto AG, van Miert AS: Trimethoprim-sulfonamide combinations in the horse: a review. J Vet Pharmacol Ther 17:64–73, 1994. PUBMED Abstract
  55. Papich MG, Korsrud GO, Boison JO, et al: A study of the disposition of procaine penicillin G in feedlot steers following intramuscular and subcutaneous injection. J Vet Pharmacol Ther 16:317–327, 1993. PUBMED Abstract
  56. Firth EC, Nouws JFM, Driessens F, et al: Effect of the injection site on the pharmacokinetics of procaine penicillin G in horses. Am J Vet Res 47:2380–2383, 1986. PUBMED Abstract
  57. Baggot JD: Bioavailability and bioequivalence of veterinary drug dosage forms, with particular reference to horses: an overview. J Vet Pharmacol Ther 15(2):160–173, 1992. PUBMED Abstract
  58. Ensink JM, Klein WR, Mevius DJ, et al: Bioavailability of oral penicillins in the horse: a comparison of pivampicillin and amoxicillin. J Vet Pharmacol Ther 15:221–230, 1992. PUBMED Abstract
  59. Wilson WD, Spensley MS, Baggot JD, et al: Pharmacokinetics and estimated bioavailability of amoxicillin in mares, after intravenous, intramuscular, and oral administration. Am J Vet Res 49:1688–1693, 1988. PUBMED Abstract
  60. Ensink JM, Vulto AG, van Miert AS, et al: Oral bioavailability an in vitro stability of pivampicillin, bacampicillin, talampicillin, and ampicillin in horses. Am J Vet Res 57: 1021–1024, 1996. PUBMED Abstract
  61. Baggot JD: Bioavailability and disposition kinetics of amoxicillin in neonatal foals. Equine Vet J 20:125–127, 1988. PUBMED Abstract
  62. Duffee NE, Christensen JM, Craig AM: The pharmacokinetics of cefadroxil in the foal. J Vet Pharmacol Ther 12:322–326, 1989. PUBMED Abstract
  63. Wilson WD, Baggot JD, Adamson PJW, et al: Cefadroxil in the horse: pharmacokinetics and in vitro antibacterial activity. J Vet Pharmacol Ther 8:246–253, 1985. PUBMED Abstract
  64. Davis JL, Salmon JH, Papich MG: Pharmacokinetics and tissue distribution of cephalexin in the horse after oral and intravenous administration. J Vet Pharmacol Ther 28:425–431, 2005. PUBMED Abstract
  65. Lakritz J, Wilson WD, Marsh AE, et al: Effects of prior feeding on pharmacokinetics and estimated bioavailability after oral administration of a single dose of microencapsulated erythromycin base in healthy foals. Am J Vet Res 61:1011–1015, 2000. PUBMED Abstract
  66. Lakritz J, Wilson WD, Marsh AE, et al: Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals. Am J Vet Res 61:914–919, 2000. PUBMED Abstract
  67. Carrillo NA, Giguère S, Gronwall, et al: Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory concentration of the drug against common bacterial pathogens of horses. Am J Vet Res 66:30–35, 2005. PUBMED Abstract
  68. van Duijkeren E, Kessels BG, Sloet van Oldruitenborgh-Oosterbaan MM, et al: In vitro and in vivo binding of trimethoprim and sulphachlorpyridazine to equine food and digesta and their stability in caecal contents. J Vet Pharmacol Ther 19(4):281–287, 1996. PUBMED Abstract
  69. Van Duijkeren E, Vulto AG, Sloet van Oldruitenborgh-Oosterbaan MM, et al: Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. J Vet Pharmacol Ther 18(1):47–53, 1995. PUBMED Abstract
  70. Lloyd KCK, Stover SM, Pascoe JR, et al: Plasma and synovial fluid concentrations of gentamicin in horses after intra-articular administration of buffered and unbuffered gentamicin. Am J Vet Res 49:644–649, 1988. PUBMED Abstract
  71. Lescun TB, Ward MP, Adams SB: Gentamicin concentrations in synovial fluid and joint tissues during intravenous administration or continuous intra-articular infusion of the tarsocrural joint of clinically normal horses. Am J Vet Res 67(3):409–416, 2006. PUBMED Abstract
  72. Mills ML, Rush BR, St Jean G, et al: Determination of synovial fluid and serum concentrations, and morphologic effects of intraarticular ceftiofur sodium in horses. Vet Surg 29(5):398–406, 2000. PUBMED Abstract
  73. Rubio-Martinez LM, Cruz AM: Antimicrobial regional limb perfusion in horses. J Am Vet Med Assoc 228(5):706–712, 2006. PUBMED Abstract
  74. Murphey ED, Santschi EM, Papich MG: Regional intravenous perfusion of the distal limb of horses with amikacin sulfate. J Vet Pharmacol Ther 22:68–71, 1999. PUBMED Abstract
  75. Caprile KA, Short CR: Pharmacologic considerations in drug therapy in foals. Vet Clin North Am Equine Pract 3:123, 1987. PUBMED Abstract
  76. Pinto N, Schumacher J, Taintor J, et al: Pharmacokinetics of amikacin in plasma and selected body fluids of healthy horses after a single intravenous dose. Equine Vet J 43(1):112–116, 2011. PUBMED Abstract
  77. McFarlane D, Papich MG, Breuhaus B, et al: Pharmacokinetics of amikacin sulfate in sick and healthy foals. In Proceedings of the 5th Conference of the International Veterinary Emergency and Critical Care Society, 1996, San Antonio, Texas (abstract).
  78. Bucki EP, Giguère S, Macpherson M, et al: Pharmacokinetics of once-daily amikacin in healthy foals and therapeutic drug monitoring in hospitalized equine neonates. J Vet Intern Med 18(5):728–733, 2004. PUBMED Abstract
  79. Orsini JA, Soma LR, Rourke JE, et al: Pharmacokinetics of amikacin in the horse following intravenous and intramuscular administration. J Vet Pharmacol Ther 8(2):194–201, 1985. PUBMED Abstract
  80. Rossdale PD, Cash RS, Leadon DP, et al: Biochemical constituents of cerebrospinal fluid in premature and full term foals. Equine Vet J 14(2):134–138, 1982. PUBMED Abstract
  81. Adamson PJ, Wilson WD, Baggot JD, et al: Influence of age on the disposition kinetics of chloramphenicol in equine neonates. Am J Vet Res 52(3):426–431, 1991. PUBMED Abstract
  82. Bermingham EC, Papich MG, Vivrette SL: Pharmacokinetics of enrofloxacin administered intravenously and orally to foals. Am J Vet Res 61(6):706–709, 2000. PUBMED Abstract
  83. Prescott JF, Staempfli HR, Barker IK, et al: A method for reproducing fatal idiopathic colitis (colitis X) in ponies and isolation of a clostridium as a possible agent. Equine Vet J 20(6):417–420, 1988. PUBMED Abstract
  84. Brashier MK, Geor RJ, Ames TR, et al: Effect of intravenous calcium administration on gentamicin-induced nephrotoxicosis in ponies. Am J Vet Res 59(8):1055–1062, 1998. PUBMED Abstract
  85. Riond JL, Riviere JE, Duckett WM, et al: Cardiovascular effects and fatalities associated with intravenous administration of doxycycline to horses and ponies. Equine Vet J 24(1):41–45, 1992. PUBMED Abstract
  86. Bowen JM, McMullan WC: Influence of induced hypermagnesemia and hypocalcemia on neuromuscular blocking property of oxytetracycline in the horse. Am J Vet Res 36(7):1025–1028, 1975. PUBMED Abstract
  87. Yoon JH, Brooks RL Jr, Khan A, et al: The effect of enrofloxacin on cell proliferation and proteoglycans in horse tendon cells. Cell Biol Toxicol 20(1):41–54, 2004. PUBMED Abstract
  88. Egerbacher M, Edinger J, Tschulenk W: Effects of enrofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture. Am J Vet Res 62(5):704–708, 2001. PUBMED Abstract
  89. Bertone AL, Tremaine WH, Macoris DG, et al: Effect of long-term administration of an injectable enrofloxacin solution on physical and musculoskeletal variables in adult horses. J Am Vet Med Assoc 217(10):1514–1521, 2000. PUBMED Abstract
  90. Madison JB, Garber JL, Rice B, et al: Effect of oxytetracycline on metacarpophalangeal and distal interphalangeal joint angles in newborn foals. J Am Vet Med Assoc 204(2):246–249, 1994. PUBMED Abstract
  91. Kasper CA, Clayton HM, Wright AK, et al: Effect of high doses of oxytetracycline on metacarpophalangeal joint kinematics in neonatal foals. J Am Vet Med Assoc 207:65–73, 1995. PUBMED Abstract
  92. Papich MG, Wright AK, Petrie L, et al: Pharmacokinetics of oxytetracycline administered intravenously to 4- to 5-day-old foals. J Vet Pharmacol Ther 18(5):375–378, 1995. PUBMED Abstract
  93. Aho P, Mannisto PT: Effects of two erythromycins, doxycycline and phenoxymethylpenicillin on human leucocyte chemotaxis in vitro. J Antimicrob Chemother 21(suppl D):29–32, 1988. PUBMED Abstract
  94. Healy DP, Silverman PA, Neely AN, et al: Effect of antibiotics on polymorphonuclear neutrophil apoptosis. Pharmacotherapy 22(5):578–585, 2002. PUBMED Abstract
  95. Back O, Norberg B: The effect of a therapeutic doxycycline concentration on polymorphonuclear leukocyte migration in vitro. Scand J Infect Dis 16(4):369–372, 1984. PUBMED Abstract
  96. Back O, Norberg B: Effect of a single oral dose of doxycycline on polymorphonuclear leukocyte migration in a casein gradient. Eur J Clin Pharmacol 28(2):193–195, 1985. PUBMED Abstract
  97. Krakauer T, Buckley M: Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 47(11):3630–3633, 2003. PUBMED Abstract
  98. Hanemaaijer R, Visser H, Koolwijk P, et al: Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 12(2):114–118, 1998. PUBMED Abstract
  99. Solomon A, Rosenblatt M, Li DQ, et al: Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 41(9):2544–2557, 2000. PUBMED Abstract
  100. Brooks DE, Ollivier FJ: Matrix metalloproteinase inhibition in corneal ulceration. Vet Clin North Am Small Anim Pract 34(3):611–622, 2004. PUBMED Abstract
  101. Krakauer T, Pitt L, Hunt RE: Detection of interleukin-6 and interleukin-2 in serum of rhesus monkeys exposed to a nonlethal dose of staphylococcal enterotoxin B. Mil Med 62(9):612–615, 1997. PUBMED Abstract
  102. Fortier LA, Motta T, Greenwald RA, et al: Synoviocytes are more sensitive than cartilage to the effects of minocycline and doxycycline on IL-1alpha and MMP-13-induced catabolic gene responses. J Orthop Res 28(4):522–528, 2010. PUBMED Abstract
  103. Bamias G, Marini M, Moskaluk CA, et al: Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol 169(9):5308–5314, 2002. PUBMED Abstract
  104. Koenig JB, Cote N, LaMarre J, et al: Binding of radiolabeled porcine motilin and erythromycin lactobionate to smooth muscle membranes in various segments of the equine gastrointestinal tract. Am J Vet Res 63(11):1545–1550, 2002. PUBMED Abstract
  105. Durando MM, MacKay RJ, Linda S, et al: Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 55(7):921–927, 1994. PUBMED Abstract
  106. Parviainen AK, Barton MH, Norton NN: Evaluation of polymyxin B in an ex vivo model of endotoxemia in horses. Am J Vet Res 62(1):72–76, 2001. PUBMED Abstract
  107. Barton MH: Update on equine therapeutics: use of polymyxin B for treatment of endotoxemia in horses. Compend Contin Educ Equine Pract 22(11):1056–1059, 2000.
  108. Morresey PR, MacKay RJ: Endotoxin-neutralizing activity of polymyxin B in blood after IV administration in horses. Am J Vet Res 67(4):642–647, 2006. PUBMED Abstract
  109. Goudah A, Abo El-Sooud K, Shim JH, et al: Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. J Vet Pharmacol Ther 31(5):399–405, 2008. PUBMED Abstract
  110. Clode AB, Davis JL, Salmon J, et al: Aqueous humor and plasma concentrations of ciprofloxacin and moxifloxacin following topical ocular administration in ophthalmologically normal horses. Am J Vet Res 65(5):564–569, 2010. PUBMED Abstract
  111. Divers TJ, Irby NL, Mohammed HO, et al: Ocular penetration of intravenously administered enrofloxacin in the horse. Equine Vet J 40(2):167–170, 2008. PUBMED Abstract
  112. Art T, de Moffarts B, Bedoret D, et al: Pulmonary function and antimicrobial concentration after marbofloxacin inhalation in horses. Vet Rec 161(10):348–350, 2007. PUBMED Abstract
  113. González F, Rodríguez C, De Lucas JJ, et al: Pharmacokinetics of a single intravenous dose of marbofloxacin in adult donkeys. Vet Rec 161(4):133–136, 2007. PUBMED Abstract
  114. Kum C, Gokbulut C, Sekkin S, et al: Pharmacokinetics of danofloxacin following intravenous and intramuscular administration in donkeys. J Vet Pharmacol Ther 32(1):105–108, 2009. PUBMED Abstract
  115. Clark C, Dowling PM, Ross S, et al: Pharmacokinetics of tilmicosin in equine tissues and plasma. J Vet Pharmacol Ther 31(1):66–70, 2008. PUBMED Abstract
  116. Scheuch E, Spieker J, Venner M, et al: Quantitative determination of the macrolide antibiotic tulathromycin in plasma and broncho-alveolar cells of foals using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 850(1-2):464–470, 2007. PUBMED Abstract
  117. Carlson K, Kuskie K, Chaffin K, et al: Antimicrobial activity of Tulathromycin and 14 other antimicrobials against virulent Rhodococcus equi in vitro. Vet Ther 11(2):E1–9, 2010. PUBMED Abstract
  118. Jacks S, Giguere S, Gronwall PR, et al: Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals. Am J Vet Res 62(12):1870–1875, 2001. PUBMED Abstract
  119. Berghaus LJ, Giguère S, Sturgill TL, et al: Plasma pharmacokinetics, pulmonary distribution, and in vitro activity of gamithromycin in foals. J Vet Pharmacol Therap 35:59–66, 2012. PUBMED Abstract
  120. Javsicas LH, Giguère S, Womble AY: Disposition of oral telithromycin in foals and in vitro activity of the drug against macrolide-susceptible and macrolide-resistant Rhodococcus equi isolates. J Vet Pharmacol Ther 33(4):383–388,2010. PUBMED Abstract
  121. Leclere M, Magdesian KG, Cole CA, et al: Pharmacokinetics and preliminary safety evaluation of azithromycin in adult horses. J Vet Pharmacol Ther 35(6):541–549, 2012. PUBMED Abstract
  122. Meyer S, Giguère S, Rodriguez R, et al: Pharmacokinetics of intravenous ceftiofur sodium and concentration in body fluids of foals. J Vet Pharmacol Ther 32(4):309–316, 2009. PUBMED Abstract
  123. Hall TL, Tell LA, Wetzlich SE, et al: Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals. J Vet Pharmacol Ther 34(4):403–409, 2011. PUBMED Abstract
  124. Collard WT, Cox SR, Lesman SP, et al: Pharmacokinetics of ceftiofur crystalline-free acid sterile suspension in the equine. J Vet Pharmacol Ther 34(5):476–481, 2011. PUBMED Abstract
  125. Giguère S, Sturgill TL, Berghaus LJ, et al: Effects of two methods of administration on the pharmacokinetics of ceftiofur crystalline free acid in horses. J Vet Pharmacol Ther 34(2):193–196, 2011. PUBMED Abstract
  126. Credille BC, Giguère S, Berghaus LJ, et al: Plasma and pulmonary disposition of ceftiofur and its metabolites after intramuscular administration of ceftiofur crystalline free acid in weanling foals. J Vet Pharmacol Ther 35(3):259–264, 2012. PUBMED Abstract
  127. Orsini JA, Moate PJ, Boston RC, et al: Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses. J Vet Pharmacol Ther 28(4):355–361, 2005. PUBMED Abstract
  128. Hubenov H, Bakalov D, Krastev S, et al: Pharmacokinetic studies on tobramycin in horses. J Vet Pharmacol Ther 30(4):353–357, 2007. PUBMED Abstract
  129. Greko C, Bengtsson B, Franklin A, et al: Efficacy of trimethoprim-sulfadoxine against Escherichia coli in a tissue cage model in calves. J Vet Pharmacol Ther 25:413–423, 2002. PUBMED Abstract
  130. Van Duijkeren E, Ensink JM, Meijer LA: Distribution of orally administered trimethoprim and sulfadiazine into noninfected subcutaneous tissue chambers in adult ponies. J Vet Pharmacol Ther 25:273–277, 2002. PUBMED Abstract
  131. Brown MP, Gronwall R, Castro L: Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. Am J Vet Res 49:918–922, 1988. PUBMED Abstract
  132. Bertone AL, Jones RL, McIlwraith CW: Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis. Am J Vet Res 49:1681–1686, 1988. PUBMED Abstract
  133. Womble A, Giguère S, Lee EA: Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals. J Vet Pharmacol Ther 30(3):187–193, 2007. PUBMED Abstract
  134. Schnabel LV, Papich MG, Watts AE, et al: Orally administered doxycycline accumulates in synovial fluid compared to plasma. Equine Vet J 42(3):208–212, 2010. PUBMED Abstract
  135. Baker A, Plummer CE, Szabo NJ, et al: Doxycycline levels in preocular tear film of horses following oral administration. Vet Ophthalmol 11(6):381–385, 2008. PUBMED Abstract
  136. McKellar QA, Varma KJ: Pharmacokinetics and tolerance of florfenicol in Equidae. Eq Vet J 28(3):209–213, 1996.
  137. Britzi M, Gross M, Lavy E, et al: Bioavailability and pharmacokinetics of metronidazole in fed and fasted horses. J Vet Pharmacol Ther 33(5):511–514, 2010. PUBMED Abstract
  138. Venner M, Peters J, Höhensteiger N, et al: Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals. Naunyn Schmiedebergs Arch Pharmacol 381(2):161–169, 2010. PUBMED Abstract
  139. Peters J, Block W, Oswald S, et al: Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. Drug Metab Dispos 39(9):1643–1649, 2011. PUBMED Abstract
  140. Peters J, Eggers K, Oswald S, et al: Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. Drug Metab Dispos 40(3):522–528, 2012. PUBMED Abstract
  141. Paxson JA, Paradis MR: Pharmacokinetics of aztreonam after intravenous administration in foals. J Vet Pharmacol Ther 34(1):92–94, 2011. PUBMED Abstract
  142. Zozaya DH, Gutiérrez OL, Ocampo CL, et al: Pharmacokinetics of a single bolus intravenous, intramuscular and subcutaneous dose of disodium fosfomycin in horses. J Vet Pharmacol Ther 31(4):321–327, 2008. PUBMED Abstract
  143. Prades M, Brown MP, Gronwall R, et al: Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. Equine Vet J 21(3):211–214, 1989. PUBMED Abstract
  144. Taintor J, Crowe C, Hancock S, et al: Treatment of conidiobolomycosis with fluconazole in two pregnant mares. J Vet Intern Med 18(3):363–364, 2004. PUBMED Abstract
  145. Davis JL, Salmon JH, Papich MG: Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. Am J Vet Res 66(10):1694–1701, 2005. PUBMED Abstract
  146. Davis EW, Legendre AM: Successful treatment of guttural pouch mycosis with itraconazole and topical enilconazole in a horse. J Vet Intern Med 8(4):304–305, 1994. PUBMED Abstract
  147. Foley JP, Legendre AM: Treatment of coccidioidomycosis osteomyelitis with itraconazole in a horse: a brief report. J Vet Intern Med 6(6):333–334, 1992. PUBMED Abstract
  148. Korenek NL, Legendre AM, Andrews FM, et al: Treatment of mycotic rhinitis with itraconazole in three horses. J Vet Intern Med 8(3):224–227, 1994. PUBMED Abstract
  149. Davis JL, Salmon JH, Papich MG: The pharmacokinetics of voriconazole in the horse following oral and intravenous administration. Am J Vet Res 67(6):1070–1075, 2006. PUBMED Abstract
  150. Passler NH, Chan HM, Stewart AJ, et al. Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing. J Vet Pharmacol Ther 33(1):35–41, 2010. PUBMED Abstract
  151. Madison JB, Reid BV, Raskin RE: Amphotericin B treatment of Candida arthritis in two horses. J Am Vet Med Assoc 206(3):338–341, 1995. PUBMED Abstract
  152. Reilly LK, Palmer JE: Systemic candidiasis in four foals. J Am Vet Med Assoc 205(3):464–466, 1994. PUBMED Abstract
  153. Schutte JG, van den Ingh TS: Microphthalmia, brachygnathia superior, and palatocheiloschisis in a foal associated with griseofulvin administration to the mare during early pregnancy. Vet Q 19(2):58–60, 1997. PUBMED Abstract
  154. Williams MM, Davis EG, KuKanich B: Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. J Vet Pharmacol Ther 34(3):232–237, 2011. PUBMED Abstract
  155. Rees WA, Harkins JD, Woods WE, et al: Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. Equine Vet J 29(2):104–110, 1997. PUBMED Abstract
  156. Rees WA, Harkins JD, Lu M, et al: Pharmacokinetics and therapeutic efficacy of rimantadine in horses experimentally infected with influenza virus A2. Am J Vet Res 60(7):888–894, 1999. PUBMED Abstract
  157. Friday PA, Scarratt WK, Elvinger F, et al: Ataxia and paresis with equine herpesvirus type 1 infection in a herd of riding school horses. J Vet Intern Med 14(2):197–201, 2000. PUBMED Abstract
  158. Murray MJ, del Piero F, Jeffrey SC, et al: Neonatal equine herpesvirus type 1 infection on a Thoroughbred breeding farm. J Vet Intern Med 12(1):36–41, 1998. PUBMED Abstract
  159. Wilkins PA: Acyclovir in the treatment of EHV-1 myeloencephalopathy. Proc Am Coll Vet Int Med 170–172, 2004.
  160. Wilkins PA, Papich MG, Sweeney RW: Pharmacokinetics of acyclovir in adult horses. J Vet Emerg Crit Care 15(3):174–178, 2005.
  161. Maxwell LK, Bentz BG, Bourne DW, et al: Pharmacokinetics of valacyclovir in the adult horse. J Vet Pharmacol Ther 31(4):312–320, 2008. PUBMED Abstract
  162. Garré B, Shebany K, Gryspeerdt A, et al: Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob Agents Chemother 51(12):4308–4314, 2007. PUBMED Abstract
  163. Garré B, Baert K, Nauwynck H, et al: Multiple oral dosing of valacyclovir in horses and ponies. J Vet Pharmacol Ther 32(3):207–212, 2009. PUBMED Abstract
  164. Tsujimura K, Yamada M, Nagata S, et al: Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. J Vet Med Sci 72(3):357–361, 2010. PUBMED Abstract
  165. Yamanaka T, Tsujimura K, Kondo T, et al. Efficacy of oseltamivir phosphate to horses inoculated with equine influenza A virus. J Vet Med Sci 68(9):923–928, 2008.
  166. Yamanaka T, Yamada M, Tsujimura K, et al: Clinical pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate after oral administration in horses. J Vet Med Sci 69(3):293–296, 2007. PUBMED Abstract
  167. Lindsay DS, Butler JM, Rippey NS, et al: Demonstration of synergistic effects of sulfonamides and dihydrofolate reductase/thymidylate synthase inhibitors against Neospora caninum tachyzoites in cultured cells, and characterization of mutants resistant to pyrimethamine. Am J Vet Res 57(1):68–72, 1996. PUBMED Abstract
  168. Piercy RJ, Hinchcliff KW, Reed SM: Folate deficiency during treatment with orally administered folic acid, sulphadiazine and pyrimethamine in a horse with suspected equine protozoal myeloencephalitis (EPM). Equine Vet J 34(3):311–316, 2002. PUBMED Abstract
  169. Toribio RE, Bain FT, Mrad DR, et al: Congenital defects in newborn foals of mares treated for equine protozoal myeloencephalitis during pregnancy. J Am Vet Med Assoc 212(5):697–701, 1998. PUBMED Abstract
  170. Dirikolu L, Lehner F, Nattrass C, et al: Diclazuril in the horse: its identification and detection and preliminary pharmacokinetics. J Vet Pharmacol Ther 22(6):374–379, 1999. PUBMED Abstract
  171. Belloli C, Crescenzo G, Lai O, et al: Pharmacokinetics of imidocarb dipropionate in horses after intramuscular administration. Equine Vet J 34(6):625–629, 2002. PUBMED Abstract